Summary

Viral Vectors for Non-human Primates Market – Scope of Report
TMR’s report on the global viral vectors for non-human primates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global viral vectors for non-human primates market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global viral vectors for non-human primates market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the viral vectors for non-human primates market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global viral vectors for non-human primates market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global viral vectors for non-human primates market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global viral vectors for non-human primates market.

The report delves into the competitive landscape of the global viral vectors for non-human primates market. Key players operating in the global viral vectors for non-human primates market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global viral vectors for non-human primates market profiled in this report.

Key Questions Answered in Global viral vectors for non-human primates Market Report
• What is the sales/revenue generated by viral vectors for non-human primates across all regions during the forecast period?
• What are the opportunities in the global viral vectors for non-human primates market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Viral Vectors for Non-human Primates Market – Research Objectives and Research Approach
The comprehensive report on the global viral vectors for non-human primates market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global viral vectors for non-human primates market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global viral vectors for non-human primates market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Viral Vectors for Non-human Primates Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, 2020-2034
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Recent Advancements in Viral Vector Technology
5.2. Porter’s Five Forces Analysis
5.3. List of Leading CROs Offering Non-human Primate based Preclinical Testing Services
5.4. PESTLE Analysis
5.5. Key Industry Events (Product Approvals, Partnerships, and Collaborations)
6. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Vector Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Vector Type, 2020-2034
6.3.1. Adenoviral Vectors
6.3.2. Adeno-associated Vectors
6.3.3. Retroviral Vectors
6.3.4. Lentiviral Vectors
6.3.5. Others
6.4. Market Attractiveness By Vector Type
7. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Type of Non-human Primates
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
7.3.1. Marmosets
7.3.2. Rhesus macaques
7.3.3. Cynomolgus monkey
7.3.4. Others
7.4. Market Attractiveness By Type of Non-human Primates
8. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Application, 2020-2034
8.3.1. Gene Therapy
8.3.2. Vaccine Research
8.4. Market Attractiveness By Application
9. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Therapeutic Area
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Therapeutic Area, 2020-2034
9.3.1. Genetic Disorders
9.3.2. Infectious Diseases
9.3.3. Oncological Disorders
9.3.4. Others
9.4. Market Attractiveness By Therapeutic Area
10. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast By End-user, 2020-2034
10.3.1. Pharmaceutical and Biotechnology Companies
10.3.2. Academic and Research Institutions
10.4. Market Attractiveness By End-user
11. Global Viral Vectors for Non-human Primates Market Analysis and Forecasts, By Region
11.1. Key Findings
11.2. Market Value Forecast By Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness By Region
12. North America Viral Vectors for Non-human Primates Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Vector Type, 2020-2034
12.2.1. Adenoviral Vectors
12.2.2. Adeno-associated Vectors
12.2.3. Retroviral Vectors
12.2.4. Lentiviral Vectors
12.2.5. Others
12.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
12.3.1. Marmosets
12.3.2. Rhesus macaques
12.3.3. Cynomolgus monkey
12.3.4. Others
12.4. Market Value Forecast By Application, 2020-2034
12.4.1. Gene Therapy
12.4.2. Vaccine Research
12.5. Market Value Forecast By Therapeutic Area, 2020-2034
12.5.1. Genetic Disorders
12.5.2. Infectious Diseases
12.5.3. Oncological Disorders
12.5.4. Others
12.6. Market Value Forecast By End-user, 2020-2034
12.6.1. Pharmaceutical and Biotechnology Companies
12.6.2. Academic and Research Institutions
12.7. Market Value Forecast By Country, 2020-2034
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Vector Type
12.8.2. By Type of Non-human Primates
12.8.3. By Application
12.8.4. By Therapeutic Area
12.8.5. By End-user
12.8.6. By Country
13. Europe Viral Vectors for Non-human Primates Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Vector Type, 2020-2034
13.2.1. Adenoviral Vectors
13.2.2. Adeno-associated Vectors
13.2.3. Retroviral Vectors
13.2.4. Lentiviral Vectors
13.2.5. Others
13.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
13.3.1. Marmosets
13.3.2. Rhesus macaques
13.3.3. Cynomolgus monkey
13.3.4. Others
13.4. Market Value Forecast By Application, 2020-2034
13.4.1. Gene Therapy
13.4.2. Vaccine Research
13.5. Market Value Forecast By Therapeutic Area, 2020-2034
13.5.1. Genetic Disorders
13.5.2. Infectious Diseases
13.5.3. Oncological Disorders
13.5.4. Others
13.6. Market Value Forecast By End-user, 2020-2034
13.6.1. Pharmaceutical and Biotechnology Companies
13.6.2. Academic and Research Institutions
13.7. Market Value Forecast By Country, 2020-2034
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Spain
13.7.5. Italy
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Vector Type
13.8.2. By Type of Non-human Primates
13.8.3. By Application
13.8.4. By Therapeutic Area
13.8.5. By End-user
13.8.6. By Country
14. Asia Pacific Viral Vectors for Non-human Primates Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Vector Type, 2020-2034
14.2.1. Adenoviral Vectors
14.2.2. Adeno-associated Vectors
14.2.3. Retroviral Vectors
14.2.4. Lentiviral Vectors
14.2.5. Others
14.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
14.3.1. Marmosets
14.3.2. Rhesus macaques
14.3.3. Cynomolgus monkey
14.3.4. Others
14.4. Market Value Forecast By Application, 2020-2034
14.4.1. Gene Therapy
14.4.2. Vaccine Research
14.5. Market Value Forecast By Therapeutic Area, 2020-2034
14.5.1. Genetic Disorders
14.5.2. Infectious Diseases
14.5.3. Oncological Disorders
14.5.4. Others
14.6. Market Value Forecast By End-user, 2020-2034
14.6.1. Pharmaceutical and Biotechnology Companies
14.6.2. Academic and Research Institutions
14.7. Market Value Forecast By Country, 2020-2034
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Vector Type
14.8.2. By Type of Non-human Primates
14.8.3. By Application
14.8.4. By Therapeutic Area
14.8.5. By End-user
14.8.6. By Country
15. Latin America Viral Vectors for Non-human Primates Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Vector Type, 2020-2034
15.2.1. Adenoviral Vectors
15.2.2. Adeno-associated Vectors
15.2.3. Retroviral Vectors
15.2.4. Lentiviral Vectors
15.2.5. Others
15.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
15.3.1. Marmosets
15.3.2. Rhesus macaques
15.3.3. Cynomolgus monkey
15.3.4. Others
15.4. Market Value Forecast By Application, 2020-2034
15.4.1. Gene Therapy
15.4.2. Vaccine Research
15.5. Market Value Forecast By Therapeutic Area, 2020-2034
15.5.1. Genetic Disorders
15.5.2. Infectious Diseases
15.5.3. Oncological Disorders
15.5.4. Others
15.6. Market Value Forecast By End-user, 2020-2034
15.6.1. Pharmaceutical and Biotechnology Companies
15.6.2. Academic and Research Institutions
15.7. Market Value Forecast By Country, 2020-2034
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Vector Type
15.8.2. By Type of Non-human Primates
15.8.3. By Application
15.8.4. By Therapeutic Area
15.8.5. By End-user
15.8.6. By Country
16. Middle East & Africa Viral Vectors for Non-human Primates Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast By Vector Type, 2020-2034
16.2.1. Adenoviral Vectors
16.2.2. Adeno-associated Vectors
16.2.3. Retroviral Vectors
16.2.4. Lentiviral Vectors
16.2.5. Others
16.3. Market Value Forecast By Type of Non-human Primates, 2020-2034
16.3.1. Marmosets
16.3.2. Rhesus macaques
16.3.3. Cynomolgus monkey
16.3.4. Others
16.4. Market Value Forecast By Application, 2020-2034
16.4.1. Gene Therapy
16.4.2. Vaccine Research
16.5. Market Value Forecast By Therapeutic Area, 2020-2034
16.5.1. Genetic Disorders
16.5.2. Infectious Diseases
16.5.3. Oncological Disorders
16.5.4. Others
16.6. Market Value Forecast By End-user, 2020-2034
16.6.1. Pharmaceutical and Biotechnology Companies
16.6.2. Academic and Research Institutions
16.7. Market Value Forecast By Country, 2020-2034
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Vector Type
16.8.2. By Type of Non-human Primates
16.8.3. By Application
16.8.4. By Therapeutic Area
16.8.5. By End-user
16.8.6. By Country
17. Competition Landscape
17.1. Market Player - Competition Matrix (By Tier and Size of companies)
17.2. Market Share Analysis By Company (2023)
17.3. Market Footprint Analysis
17.3.1. By Region
17.3.2. By Vector Type
17.4. Competitive Snapshot
17.5. Company Profiles
17.5.1. Lonza
17.5.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.1.2. Product Portfolio
17.5.1.3. Financial Overview
17.5.1.4. SWOT Analysis
17.5.1.5. Strategic Overview
17.5.2. Thermo Fisher Scientific Inc
17.5.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.2.2. Product Portfolio
17.5.2.3. Financial Overview
17.5.2.4. SWOT Analysis
17.5.2.5. Strategic Overview
17.5.3. Revvity
17.5.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.3.2. Product Portfolio
17.5.3.3. Financial Overview
17.5.3.4. SWOT Analysis
17.5.3.5. Strategic Overview
17.5.4. VectorBuilder Inc.
17.5.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.4.2. Product Portfolio
17.5.4.3. Financial Overview
17.5.4.4. SWOT Analysis
17.5.4.5. Strategic Overview
17.5.5. Creative Biolabs
17.5.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.5.2. Product Portfolio
17.5.5.3. Financial Overview
17.5.5.4. SWOT Analysis
17.5.5.5. Strategic Overview
17.5.6. Takara Bio Inc
17.5.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.6.2. Product Portfolio
17.5.6.3. Financial Overview
17.5.6.4. SWOT Analysis
17.5.6.5. Strategic Overview
17.5.7. MERCK KGaA
17.5.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.7.2. Product Portfolio
17.5.7.3. Financial Overview
17.5.7.4. SWOT Analysis
17.5.7.5. Strategic Overview
17.5.8. Andelyn Biosciences
17.5.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.8.2. Product Portfolio
17.5.8.3. Financial Overview
17.5.8.4. SWOT Analysis
17.5.8.5. Strategic Overview
17.5.9. Biovian Oy
17.5.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.9.2. Product Portfolio
17.5.9.3. Financial Overview
17.5.9.4. SWOT Analysis
17.5.9.5. Strategic Overview
17.5.10. Genezen
17.5.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.5.10.2. Product Portfolio
17.5.10.3. Financial Overview
17.5.10.4. SWOT Analysis
17.5.10.5. Strategic Overview